Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Key Points Company and Industry 1. Company: Eli Lilly and Company (NYSE:LLY) 2. Event: 43rd Annual J.P. Morgan Healthcare Conference 3. Date: January 14, 2025 4. Participants: - Dave Ricks - Chairman and CEO of Eli Lilly - Chris Schott - JPMorgan [1] Core Views and Arguments 1. Disappointment in Meeting Expectations: Eli Lilly acknowledges missing their own expectations but emphasizes the unprecedented nature of their business in terms of size, scale, and growth rate. 2. Year 2024 Performance: The company ended the year with $4 billion over their first-time guide, achieving a 32% growth rate on a strong base, with a Q4 exit growth rate of 45%. 3. Zepbound Impact: The launch of Zepbound contributed significantly to the company's growth during the year. [2][3] Other Important Content 1. Learning from Challenges: Eli Lilly acknowledges learning from their challenges in meeting expectations and aims to improve guidance for the future. 2. Focus on Growth: The company continues to focus on growth, leveraging the success of Zepbound and other initiatives. [2][3]